Compare · GUTS vs WST
GUTS vs WST
Side-by-side comparison of Fractyl Health Inc. (GUTS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GUTS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.96B, about 488.5x GUTS ($55.2M).
- Over the past year, GUTS is down 90.8% and WST is up 39.7% - WST leads by 130.5 points.
- GUTS has been more active in the news (6 items in the past 4 weeks vs 3 for WST).
- WST has more recent analyst coverage (20 ratings vs 6 for GUTS).
- Company
- Fractyl Health Inc.
- West Pharmaceutical Services Inc.
- Price
- $1.55-62.47%
- $383.81+0.18%
- Market cap
- $55.2M
- $26.96B
- 1M return
- -78.11%
- +4.70%
- 1Y return
- -90.81%
- +39.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 6
- 3
- Recent ratings
- 6
- 20
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest GUTS
- GUTS UPCOMING DEADLINE: Levi & Korsinsky Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the Firm
- SEC Form 8-K filed by Fractyl Health Inc.
- Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
- GUTS Shareholder Alert: Fractyl Health, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
- GUTS DEADLINE: Levi & Korsinsky Reminds Fractyl Health, Inc. Investors of Upcoming Securities Class Action Deadline
- Fractyl Health Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Fractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bradley William bought $39,903 worth of shares (64,516 units at $0.62), increasing direct ownership by 76% to 149,138 units (SEC Form 4)
- Fractyl Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Fractyl Health to Participate in Upcoming September Investor Conferences
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences